Fresenius poised to issue more debt for NxStage buy
German dialysis services provider Fresenius will issue debt backing its $2bn acquisition of US peer NxStage “in due course”, a source close to the situation told GlobalCapital on Tuesday.
Fresenius Medical Care North America agreed on Monday to buy all outstanding shares in Massachusetts-based medical technology firm NxStage at $30 a share.That represents a 29% premium to NxStage’s closing share price of $23.14 on Friday and represents an enterprise value of $2bn, about five times its ...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: firstname.lastname@example.org